China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million (USD 83 million) in a Series B financing round. The funding was co-led by Meituan Long-Z Fund and existing investor Lilly Asia Ventures, with additional participation from Lapam Capital. The proceeds will accelerate the research and development and regulatory clinical studies of its core electrophysiological products.
Company Overview and Product Development
Founded in 2020, EnChannel Medical is dedicated to the development of next-generation atrial fibrillation treatment products. The company is focused on creating an integrated solution for atrial fibrillation treatment, combining “magneto-electric navigation, five-dimensional mapping, and three-dimensional PFA ablation.”-Fineline Info & Tech
